A design for phase II testing of anticancer agents within a phase III clinical trial

Daniel J. Schaid; James N. Ingle; Sam Wieand; David L. Ahmann

doi:10.1016/0197-2456(88)90032-3

A design for phase II testing of anticancer agents within a phase III clinical trial

Daniel J. Schaid, James N. Ingle, Sam Wieand, David L. Ahmann

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

A design for testing new anticancer agents is proposed such that the initial testing of new agents (phase II trials) is included within the framework of a comparative clinical trial (phase III). Randomization between phase II trials and the treatment groups of the phase III trial enforces consistency of patient selection and evaluation of response criteria. Patients who progress on the phase II trials of the new agents are randomized to one of the treatments of the phase III trial. Design issues, such as sample size and power, and analysis of the proposed design, are discussed. Advantages and disadvantages of the design are illustrated by sample size calculations for a current clinical trial in advanced breast cancer.

Original language	English (US)
Pages (from-to)	107-118
Number of pages	12
Journal	Controlled Clinical Trials
Volume	9
Issue number	2
DOIs	https://doi.org/10.1016/0197-2456(88)90032-3
State	Published - Jun 1988

Keywords

Randomized design
phase II Anticancer agents
phase III survival comparison

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/0197-2456(88)90032-3

Fingerprint Dive into the research topics of 'A design for phase II testing of anticancer agents within a phase III clinical trial'. Together they form a unique fingerprint.

Cite this

@article{cd5d63e62c234392a95d86b973718c46,

title = "A design for phase II testing of anticancer agents within a phase III clinical trial",

abstract = "A design for testing new anticancer agents is proposed such that the initial testing of new agents (phase II trials) is included within the framework of a comparative clinical trial (phase III). Randomization between phase II trials and the treatment groups of the phase III trial enforces consistency of patient selection and evaluation of response criteria. Patients who progress on the phase II trials of the new agents are randomized to one of the treatments of the phase III trial. Design issues, such as sample size and power, and analysis of the proposed design, are discussed. Advantages and disadvantages of the design are illustrated by sample size calculations for a current clinical trial in advanced breast cancer.",

keywords = "Randomized design, phase II Anticancer agents, phase III survival comparison",

author = "Schaid, {Daniel J.} and Ingle, {James N.} and Sam Wieand and Ahmann, {David L.}",

year = "1988",

month = jun,

doi = "10.1016/0197-2456(88)90032-3",

language = "English (US)",

volume = "9",

pages = "107--118",

journal = "Controlled Clinical Trials",

issn = "0197-2456",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - A design for phase II testing of anticancer agents within a phase III clinical trial

AU - Schaid, Daniel J.

AU - Ingle, James N.

AU - Wieand, Sam

AU - Ahmann, David L.

PY - 1988/6

Y1 - 1988/6

N2 - A design for testing new anticancer agents is proposed such that the initial testing of new agents (phase II trials) is included within the framework of a comparative clinical trial (phase III). Randomization between phase II trials and the treatment groups of the phase III trial enforces consistency of patient selection and evaluation of response criteria. Patients who progress on the phase II trials of the new agents are randomized to one of the treatments of the phase III trial. Design issues, such as sample size and power, and analysis of the proposed design, are discussed. Advantages and disadvantages of the design are illustrated by sample size calculations for a current clinical trial in advanced breast cancer.

AB - A design for testing new anticancer agents is proposed such that the initial testing of new agents (phase II trials) is included within the framework of a comparative clinical trial (phase III). Randomization between phase II trials and the treatment groups of the phase III trial enforces consistency of patient selection and evaluation of response criteria. Patients who progress on the phase II trials of the new agents are randomized to one of the treatments of the phase III trial. Design issues, such as sample size and power, and analysis of the proposed design, are discussed. Advantages and disadvantages of the design are illustrated by sample size calculations for a current clinical trial in advanced breast cancer.

KW - Randomized design

KW - phase II Anticancer agents

KW - phase III survival comparison

UR - http://www.scopus.com/inward/record.url?scp=0023879701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023879701&partnerID=8YFLogxK

U2 - 10.1016/0197-2456(88)90032-3

DO - 10.1016/0197-2456(88)90032-3

M3 - Article

C2 - 3396362

AN - SCOPUS:0023879701

VL - 9

SP - 107

EP - 118

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 2

ER -